Several ICBs have been approved for melanoma, including the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) antibody ipilimumab and two programmed cell death protein 1 (PD-1) antibodies, nivolumab and pembrolizumab (2). The gene discussed is CTLA4; the disease is melanoma.